Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy | Zendy

Janet M. Oliver | Zendy; Christy A. Tarleton | Zendy; Laura Gilmartin | Zendy; Tereassa Archibeque | Zendy; Clifford Qualls | Zendy; Lorena Diehl | Zendy; Bridget S. Wilson | Zendy; Mark Schuyler | Zendy

Open Access

Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy

Author(s) -

Janet M. Oliver,

Christy A. Tarleton,

Laura Gilmartin,

Tereassa Archibeque,

Clifford Qualls,

Lorena Diehl,

Bridget S. Wilson,

Mark Schuyler

Publication year - 2009

Publication title -

international archives of allergy and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.696

H-Index - 100

eISSN - 1423-0097

pISSN - 1018-2438

DOI - 10.1159/000250436

Subject(s) - omalizumab , basophil , histamine , immunoglobulin e , chemokine , medicine , immunology , cytokine , basal (medicine) , asthma , inflammation , antibody , insulin

Treating asthmatics with the humanized IgE-scavenging antibody, omalizumab (rhuMAb-E25, Xolair, reduces airways inflammation and asthma symptoms. Previously, omalizumab was shown to cause a dramatic and reversible loss of cell surface high-affinity IgE receptors, FcepsilonRI, from the peripheral blood basophils of asthmatics. The consequences of receptor loss for the FcepsilonRI-mediated synthesis and release of cytokines implicated in allergic asthma have not been examined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research